Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

Blood

Volumn 99, Issue 3, 2002, Pages 1071-1078

  Chakraverty, Ronjon ^a,b,c,d,e,f   Peggs, Karl ^a,b,c,d,e,f   Chopra, Rajesh ^a,b,c,d,e,f   Milligan, Donald W ^a,b,c,d,e,f   Kottaridis, Panagiotis D ^a,b,c,d,e,f   Verfuerth, Stephanie ^a,b,c,d,e,f   Geary, Johanne ^a,b,c,d,e,f   Thuraisundaram, Dharsha ^a,b,c,d,e,f   Branson, Kate ^a,b,c,d,e,f   Chakrabarti, Suparno ^a,b,c,d,e,f   Mahendra, Premini ^a,b,c,d,e,f   Craddock, Charles ^a,b,c,d,e,f   Parker, Anne ^a,b,c,d,e,f   Hunter, Ann ^a,b,c,d,e,f   Hale, Geoff ^a,b,c,d,e,f   Waldmann, Herman ^a,b,c,d,e,f   Williams, Catherine D ^a,b,c,d,e,f   Yong, Kwee ^a,b,c,d,e,f   Linch, David C ^a,b,c,d,e,f   Goldstone, Anthony H ^a,b,c,d,e,f   Mackinnon, Stephen ^{a,b,c,d,e,f,g}   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e LEICESTER ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; FLUDARABINE; MELPHALAN;

ADULT; ARTICLE; CHIMERA; CLINICAL ARTICLE; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HIGH RISK POPULATION; HLA MATCHING; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 0036464657     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.1071     Document Type: Article

References (35)

1. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings
2. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
3. Infections in adults undergoing unrelated donor bone marrow transplantation
4. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
5. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program
6. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome
7. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
8. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities
9. Transplant-life induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
10. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
11. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
12. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
13. Mixed hematopoietic chimerism after marrow allografts: Transplantation in the ambulatory care setting
14. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
15. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation
16. A special report: Histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors
17. Reshaping human antibodies for therapy
18. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials
19. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia
20. 1994 Consensus Conference on Acute GVHD Grading
21. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma
22. Pharmacokinetics of CAM-PATH 1H in bone marrow transplant patients
23. Prevention of graft versus host disease by inactivation of host antigen-presenting cells
24. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors
25. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCRABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: Increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse
26. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: Significant differences between recipients of T-cell depleted and unmanipulated grafts
27. Transfer of specific immunity from donor to recipient of an allogeneic bone marrow graft: Effect of conditioning on the specific immune response of the graft recipient
28. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life
29. Essential role of the thymus to reconstitute naive (CD45RA+) Thelper cells after human allogeneic bone marrow transplantation
30. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation
31. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: Alloengraftment with potential preservation of fertility in women
32. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: Induction of synergistic cytotoxicity independent of reversal of apoptosis resistance
33. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
34. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect
35. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18)